FIELD: immunology.
SUBSTANCE: present invention refers to immunology. Antibody and an antibody fragment capable of binding to human IL-17A are provided. Pharmaceutical composition and the use of an antibody or antibody fragment are also contemplated.
EFFECT: invention can find further application in the therapy of various diseases mediated by human IL-17A.
10 cl, 10 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
| HETERODIMERIC BISPECIFIC ANTIBODY AGAINST TNFα/AGAINST IL-17A, SIMILAR BY STRUCTURE TO NATURAL ANTIBODY, AND ITS PRODUCTION METHOD | 2019 |
|
RU2781816C1 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| MUTANT FULLY HUMANISED ANTIBODY AGAINST HER2 AND ENCODING GENE AND THEIR APPLICATION | 2015 |
|
RU2639531C1 |
| COLLECTION AND METHODS FOR ITS USE | 2011 |
|
RU2603080C2 |
